Table 1 Mesenchymal stem/stromal cell (MSC)-based therapies for cutaneous wound healing
From: MSCs and their exosomes: a rapidly evolving approach in the context of cutaneous wounds therapy
Cell source | Model | Results | References |
|---|---|---|---|
BMMNC | In vitro | Verifying the wound healing capabilities of CD271 + MSCs | [193] |
AT | In vivo | Facilitating the wound healing MSCs through the TLR4-dependent shaping of the wound site | [194] |
BM | In vivo | Induction of the skin recovery by MSCs through the inhibition of inflammation and also enhancing the skin regeneration-related growth factors | [60] |
AT | In vivo | Inhibition of the TNF-α-dependent inflammation, enhancing the anti-inflammatory M2 macrophage quantity, and stimulating TGF-β1-mediated angiogenesis, myofibroblast differentiation, and granulation tissue establishment by ppAAc delivered MSCs | [51] |
BM | In vivo | Lower immunogenicity and higher infiltration of allogeneic BM-MSCs than allogeneic fibroblasts | [188] |
BM | In vivo | Promoting the regeneration of DEB wounds by MSCs by the formation of functional immature anchoring fibrils | [54] |
BM | In vivo | Showing the higher capacity to induce wound healing in diabetic mice by BM-MSCs than fibroblasts | [53] |
BM | In vivo | Verifying the MSCs recruitment into wound skin and stimulating wound healing by transdifferentiation into several cell types | [195] |
BM | In vivo | Promotion of MSCs differentiation ability and diabetic wound healing in diabetic mice by implantation of PEGylated graphene oxide-mediated quercetin-modified collagen hybrid scaffold loaded with MSCs | [58] |
BM | In vivo | Promoting the viability and activity of both ISCs and MSCs by their coencapsulation supporting better wound healing | [196] |
WJ | In vivo | Amelioration of the proliferation, angiogenesis, and wound healing ability of WJ-MSCs by hyperbaric oxygen in diabetic mice | [57] |
UCB | In vivo | Confirming the MSCs differentiation into keratinocyte in the wound tissue | [8] |
BFP | In vivo | Inducing wound healing by curcumin-loaded electrospun nanofibers along with MSCs as a bioactive dressing | [197] |
BM | In vivo | Stimulating diabetic wound healing by BM-MSCs delivery using N-carboxyethyl chitosan (N-chitosan), adipic acid dihydrazide (ADH), and hyaluronic acid-aldehyde (HA-ALD) hydrogel | [59] |
NA | In vivo | Inhibition of wound healing process by miR-27b du to the inhibition of MSCs migration to burned margins | [198] |
BM | In vitro | Signifying the critical role of the ERK pathway in the phenotype shift of MSCs into human sweat gland cells (SGCs) | [199] |
BM | In vivo | Facilitating wound healing in acute full-thickness skin wounds by collagen loaded with MSCs | [200] |
BM | In vivo | Verifying the positive effect of autophagy in MSC-mediated vascularization in cutaneous wound healing by adjusting the VEGF producing | [201] |
BMMNC | In vitro | Inducing the migration of skin and wound fibroblast by MSCs | [202] |
PB | In vivo | Improving the wound healing sheep skin through promoting the expression of hair-keratin (hKER) and Collagen1 gene (Col1α1) by MSCs | [203] |
AT | In vivo | Amelioration of diabetic wounds by decellularized silk fibroin scaffold primed with MSCs | [204] |
BM | In vitro | Improving the expression of ICAM-1 in MSCs leading to the promotion of their migration by TNF-α | [205] |
BMMNC | In vivo | Amelioration of wound damages by MSCs-expressing angiopoietin-1 gene | [130] |
BM | In vivo | Promoting the functions of MSCs in wound bed by their pretreatment with TGF-β1 | [206] |
AT | In vivo | Improving the wound healing rate in diabetic rats without any enhancement in volume density of the vessels and collagen fibers by MSCs | [207] |